≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback
info icon

This is a non-core endpoint: only basic statistics are computed.

Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system

DOID Endpoint Browser

C3_SPINAL_CORD_CRANIAL_AND_OTHER_CNS

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Cause of death: ICD-10 — C72
  • Cause of death: ICD-9 — 192
  • Cause of death: ICD-8 — 192
  • Cause of death: excluded ICD-9 — 1921|1923|1928
  • Cancer registry: Topography ICD-O-3 — C72
  • Cancer registry: Morphology ICD-O-3 — ANY
  • Cancer registry: Behaviour codes — 3

2 out of 7 registries used, show all original rules.

74

4. Check minimum number of events

None

74

5. Include endpoints

None

74

6. Filter based on genotype QC (FinnGen only)

71

Control definitions (FinnGen only)

Control exclude
C3_CANCER, C3_CANCER_WIDE

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF9

Similar endpoints

↥

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

All Female Male
Number of individuals 71 32 39
Unadjusted period prevalence (%) 0.01 0.01 0.02
Median age at first event (years) 52.18 49.93 54.02

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
74
Matched controls
740
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
ABB10
NOMESCO Finland
Resection of lesion of spinal canal
+∞
36.5
32
*
9391/3-C72.0
ICD-O-3
Ependymoma, NOS, of spinal cord
+∞
35.2
31
*
ABB00
NOMESCO Finland
Excision of lesion of spinal canal
+∞
27.9
25
*
H02AB02
ATC
dexamethasone; systemic
116.0
23.3
24
*
C72.00
ICD-10 Finland
Malignant tumor of the spinal cord without histology
+∞
20.8
19
*
C72.01
ICD-10 Finland
Malignant tumor of the spinal cord grade II glioma
+∞
18.5
17
*
130
Kela drug reimbursment
Malignant tumour
+∞
18.5
17
*
N03AX16
ATC
[U] pregabalin
7.3
16.5
37
89
C72.09
ICD-10 Finland
Malignant tumor of the spinal cord other histology
+∞
16.2
15
*
D43.4
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Spinal cord
+∞
15.1
14
*
N02AA05
ATC
oxycodone; systemic
7.9
13.7
23
40
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
61.7
13.4
15
*
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
155.2
12.9
13
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
14.7
12.0
20
18
A03FA01
ATC
metoclopramide; systemic, rectal
6.6
11.9
24
50
D33.43
ICD-10 Finland
Spinal cord
+∞
11.8
11
*
D33.4
ICD-10 Finland
Benign neoplasm: Spinal cord
+∞
11.8
11
*
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
33.9
11.2
14
5
ZXE20
NOMESCO Finland
More than three and less than five hours
6.4
10.8
22
46
M03BX01
ATC
baclofen; systemic
28.2
10.7
14
6
D33.40
ICD-10 Finland
Benign glioma of the spinal cord (grade I)
+∞
10.7
10
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
+∞
10.7
10
*
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
15.3
9.9
16
13
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
25.8
9.7
13
6
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
35.2
9.7
12
*
WX408
NOMESCO Finland
General anesthesy, balanced
4.8
9.7
32
102
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
5.2
9.3
24
62
L28
ICPC
Limited function/disability (L)
4.8
9.0
27
79
A04AA01
ATC
ondansetron; systemic, rectal
57.0
8.9
10
*
XKD06
NOMESCO Finland
Physiologic investigation of micturition
15.3
8.8
14
11
WF002
NOMESCO Finland
Radical radiotherapy
101.1
8.6
9
*
D33.41
ICD-10 Finland
Myxopapillary epndymoma of the spinal cord (grade I)
+∞
8.5
8
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
+∞
8.5
8
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
8.5
8
*
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.6
8.2
18
40
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
9.4
7.9
16
21
XKC03
NOMESCO Finland
Water cystometry
18.1
7.5
11
7
JN4AD
NOMESCO Finland
Body CT examination
10.5
7.4
14
16
A04AA02
ATC
granisetron; systemic, transdermal
+∞
7.4
7
*
D33.9
ICD-10 Finland
Benign neoplasm: Central nervous system, unspecified
+∞
7.4
7
*
G95.8
ICD-10 Finland
Other specified diseases of spinal cord
+∞
7.4
7
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
7.4
7
*
C72.0
ICD-10 Finland
Malignant neoplasm: Spinal cord
+∞
7.4
7
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
7.4
7
*
R4110
NOMESCO Finland
Physiotherapy
3.9
7.4
31
115
N03AE01
ATC
clonazepam; systemic
9.9
7.2
14
17
Z51.5
ICD-10 Finland
Palliative care
15.9
7.1
11
8
A49.9
ICD-10 Finland
Bacterial infection, unspecified
7.9
7.1
16
25
XX3DW
NOMESCO Finland
Time consuming IT work
12.7
7.1
12
11
JN4BD
NOMESCO Finland
Extensive body CT
9.3
7.0
14
18
N31.8
ICD-10 Finland
Other neuromuscular dysfunction of bladder
44.2
6.9
8
*
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
4.6
6.6
18
48
L03AA13
ATC
pegfilgrastim; parenteral
76.1
6.5
7
*
N18
ICPC
Paralysis/weakness
20.2
6.4
9
5
1922A
ICD-9 Finland
Malignant neoplasm of other and unspecified parts of nervous system, Spinal cord
+∞
6.3
6
*
WX402
NOMESCO Finland
General anaesthesia
3.7
6.1
24
84
R4120
NOMESCO Finland
Occupational therapy
8.0
6.1
13
19
UKC02
NOMESCO Finland
Cystoscopy
4.3
6.1
18
51

TimeCodeWAS

↥

TimeCodeWAS is a tool for exploring time-dependent associations between an endpoint and health codes (diagnoses, lab tests, procedures, etc.).

The TimeCodeWAS analysis is done in three steps:

  1. Build a matched case-control set for this endpoint. Each case is matched to 5–10 controls on sex and year of birth, and controls must be at risk at the same age as the case's age of onset. TimeCodeWAS allows for controls to be reused.
  2. Count cases and controls. For each health code, and for each time window: tally the counts into a 2×2 table. To be eligible in a time window, a case or control must have data coverage for at least 50% of that time window.
  3. Perform association tests. If all cells of the 2×2 table have N≥10, then a χ² test is performed, otherwise a Fisher's exact test is done. The corresponding p-value and confidence interval are reported below, along with the standard odds ratio when a χ² test is done, or Fisher's MLE odds ratio otherwise.

TimeCodeWAS currently uses the same default set of time windows for all the endpoints. Please reach out to us if you have suggestions for better time windows for some endpoints. The default time windows are: TimeCodeWAS time windows

Sort & Filter
Sort
Odds Ratio
among windows:
Filter
Code & OMOP
Cases and controls with code
in
Odds Ratio
in
OMOP Concept
Code (OMOP Vocabulary) [OMOP Concept ID]
OMOP Concept Class / OMOP Domain
Odds Ratio
TimeCodeWAS O.R. time legend
Cases and controls with code
TimeCodeWAS Cases and Controls percentages time legend
Neurosurgery
14 (Medicare Specialty) [38004459]
Physician Specialty / Provider
1.4e+00 3.5e+00 — — 1.0e+50 5.6e+00 4.2e+00
10.45%/2.71% 20.90%/0.75% —/— —/— 38.71%/0.00% 71.67%/0.91% 55.77%/1.84%
Inpatient Hospital
21 (CMS Place of Service) [8717]
Visit / Visit
4.0e-02 7.1e-01 3.7e+00 1.0e+50 — 2.5e+00 6.3e-01
26.87%/26.09% 13.43%/7.09% 23.88%/0.75% 10.45%/0.00% —/— 46.67%/6.85% 32.69%/20.53%
Emergency Room Visit
ER (Visit) [9203]
Visit / Visit
4.0e-01 9.0e-01 2.9e+00 — 3.4e+00 1.6e+00 5.3e-01
38.81%/29.86% 17.91%/8.14% 16.42%/1.06% —/— 19.35%/0.75% 31.67%/8.83% 32.69%/22.20%
Office Visit
OMOP4822458 (Visit) [581477]
Visit / Visit
2.3e-01 — — — 1.0e+50 3.2e+00 1.9e+00
7.46%/6.03% —/— —/— —/— 11.29%/0.00% 21.67%/1.07% 19.23%/3.51%
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 (LOINC) [3020460]
Lab Test / Measurement
-3.9e-01 6.0e-01 3.2e+00 — 2.3e+00 8.5e-01 -7.4e-02
19.40%/26.24% 22.39%/13.73% 22.39%/1.21% —/— 29.03%/3.92% 28.33%/14.46% 28.85%/30.38%
Glucose [Moles/volume] in Serum or Plasma
14749-6 (LOINC) [3013826]
Lab Test / Measurement
-3.0e-01 9.2e-01 — — 3.2e+00 1.5e+00 1.8e-01
7.46%/9.80% 8.96%/3.77% —/— —/— 17.74%/0.90% 21.67%/5.94% 15.38%/13.19%
paracetamol; oral, parenteral, rectal
N02BE01 (ATC) [21604344]
ATC 5th / Drug
2.2e-01 1.1e+00 2.7e+00 — 3.1e+00 1.0e+00 8.8e-01
29.85%/25.49% 26.87%/10.86% 11.94%/0.90% —/— 24.19%/1.36% 26.67%/11.57% 50.00%/29.22%
Emergency Medicine
93 (Medicare Specialty) [38004510]
Physician Specialty / Provider
3.2e-01 6.8e-01 3.1e+00 — — 4.6e-01 5.3e-01
14.93%/11.31% 10.45%/5.58% 14.93%/0.75% —/— —/— 10.00%/6.54% 25.00%/16.36%
pregabalin; oral
N02BF02 (ATC) [955152]
ATC 5th / Drug
— 3.1e+00 — — — — 3.1e+00
—/— 14.93%/0.75% —/— —/— —/— —/— 25.00%/1.50%

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
26
10
39.06
20.93
1.4
1.1
—
—
—
0
0
27
55
7.15
13.92
5.1
9.9
7.41
7.40
ph
0.19
18
27
21
30
9.33
9.94
3.4
10.9
24.98
25.31
mmol/l
0.12
21
30
41
177
3.95
7.91
2.9
1.9
—
—
—
0
0
52
279
3.91
6.97
7.3
6.0
1.19
1.22
mmol/l
1.72
46
242
18
47
4.74
6.73
3.8
10.2
—
—
—
0
0
47
251
3.39
6.05
2.9
2.4
—
—
estimate
—
0
0
16
33
5.89
5.86
4.8
13.9
0.61
0.74
%
0.57
16
33
20
63
3.98
5.84
3.7
9.1
103.50
104.51
mmol/l
0.38
20
63
16
34
5.71
5.73
4.8
13.6
94.20
94.17
%
0.01
16
34
16
34
5.71
5.73
4.8
13.6
1.20
1.41
%
0.43
16
34
29
129
3.05
4.88
7.0
3.7
—
—
—
0
0
8
9
9.79
4.40
3.4
1.2
—
—
—
0
0
37
202
2.66
4.12
7.5
4.9
—
—
—
0
0
35
189
2.62
3.94
3.2
1.7
—
—
—
0
0
44
266
2.61
3.92
14.0
11.3
1.23
1.21
inr
0.05
35
221
29
151
2.51
3.44
6.3
2.6
—
—
—
0
0
46
591
0.41
3.13
3.4
4.1
1.20
1.25
mmol/l
0.26
41
546
30
166
2.36
3.06
3.6
2.6
0.54
0.32
e6/l
0.32
25
117
29
160
2.34
2.97
3.7
2.5
—
0.00
estimate
—
0
5
6
9
7.13
2.92
2.5
4.6
7.39
7.41
ph
—
6
9
8
19
4.58
2.76
3.9
6.8
36.89
36.93
°c
—
8
19
44
297
2.19
2.70
8.3
3.5
9.32
11.61
umol/l
2.26
44
278
6
12
5.33
2.45
4.3
8.8
3.83
3.71
mmol/l
—
6
12
31
188
2.12
2.44
3.7
2.6
95.64
35.62
e6/l
0.51
26
137
29
172
2.13
2.42
4.4
3.5
7.41
7.40
ph
1.11
19
120
8
23
3.77
2.34
3.9
6.1
—
—
—
0
0
6
13
4.92
2.32
4.3
8.2
1.02
1.56
mmol/l
—
6
13
15
272
0.44
2.16
2.9
3.1
—
—
—
0
0
12
50
2.67
2.15
1.4
1.1
—
—
—
0
0
16
79
2.31
2.04
1.7
1.8
—
—
—
0
0
9
35
2.78
1.87
1.8
3.6
26.22
23.82
mmol/l
—
9
35
12
56
2.36
1.72
2.0
3.3
7.36
7.38
ph
—
5
30
7
25
2.98
1.69
1.4
2.8
1.40
1.21
%
—
7
25
15
78
2.16
1.69
1.3
1.8
—
—
—
0
0
5
14
3.75
1.64
3.2
1.4
781.00
407.86
mg/l
—
5
14
37
270
1.74
1.51
17.5
8.7
0.00
0.00
e9/l
-0.00
31
204
27
180
1.79
1.50
11.9
3.9
—
—
—
0
0
9
42
2.30
1.39
12.1
3.3
—
—
—
0
0
13
69
2.07
1.39
2.5
1.7
—
—
—
0
0
43
333
1.70
1.38
8.7
5.1
0.15
0.20
e9/l
2.20
37
279
42
324
1.69
1.36
8.2
5.1
0.04
0.04
e9/l
0.18
37
265
6
25
2.52
1.27
1.3
2.8
0.62
0.60
%
—
6
25
17
104
1.82
1.23
4.1
2.0
2.45
2.44
mmol/l
0.26
17
84
31
227
1.63
1.19
4.5
3.1
114.64
49.58
e6/l
0.35
26
144
38
296
1.58
1.11
7.7
5.2
26.72
30.00
%
1.00
38
282
5
21
2.48
1.11
4.2
1.4
—
—
—
0
0
50
417
1.61
1.08
6.5
3.5
—
—
—
0
0
10
53
2.03
1.07
1.3
1.7
—
—
—
0
0
0
28
0.00
1.00
0.0
1.5
—
207.60
—
0
15
48
403
1.54
0.96
8.9
3.5
—
22.33
—
0
6
24
173
1.57
0.95
7.0
3.1
0.00
0.00
estimate
-0.00
11
52
53
456
1.57
0.93
11.3
5.1
75.96
74.86
u/l
0.13
53
424
8
42
2.01
0.92
1.5
2.1
0.21
0.22
g/l
—
8
37
24
184
1.45
0.70
1.3
1.5
—
—
—
0
0
10
63
1.68
0.65
1.5
1.5
—
—
—
0
0
0
23
0.00
0.59
0.0
1.2
—
—
—
0
0
15
108
1.49
0.59
1.3
1.8
—
—
—
0
0
10
66
1.60
0.56
2.1
1.9
2.06
1.66
%
—
10
55
67
630
1.67
0.53
25.1
13.9
139.57
139.86
mmol/l
0.45
67
617
11
76
1.53
0.51
1.5
2.6
20.55
25.08
%
0.74
11
68
7
46
1.58
0.50
5.1
2.5
7.34
7.36
ph
—
7
33
11
79
1.46
0.43
2.0
1.3
—
—
—
0
0
0
16
0.00
0.41
0.0
1.5
—
—
—
0
0
0
17
0.00
0.41
0.0
1.6
—
—
—
0
0
66
625
1.52
0.41
26.2
11.2
27.89
21.56
mg/l
0.69
61
494
17
135
1.34
0.40
1.4
2.1
—
—
—
0
0
67
684
0.78
0.30
36.0
17.4
30.00
30.29
pg
0.63
67
677
67
684
0.78
0.30
36.6
17.9
39.40
40.87
%
1.76
67
676
67
684
0.78
0.30
36.4
17.6
130.81
137.43
g/l
2.70
67
677
67
684
0.78
0.30
36.1
17.5
247.78
245.15
e9/l
0.09
67
674
27
239
1.20
0.26
4.3
3.4
20.41
41.49
ng/l
0.94
17
165
5
42
1.20
0.22
4.8
2.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
0.21
—
0
5
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
3.8
—
—
—
0
0
0
13
0.00
0.21
0.0
3.9
—
14.58
—
0
13
36
334
1.15
0.19
5.8
3.1
0.00
0.00
estimate
-0.00
11
59
7
57
1.25
0.19
1.1
1.4
—
—
—
0
0
67
683
0.80
0.19
36.0
17.5
90.49
90.77
fl
0.20
67
676
37
346
1.14
0.17
6.0
3.1
0.00
0.00
estimate
-0.00
11
56
17
150
1.17
0.16
6.2
3.1
1.02
1.02
kg/l
—
8
91
36
342
1.10
0.11
6.1
3.1
0.00
0.00
estimate
-0.00
11
59
15
135
1.14
0.10
7.1
3.7
—
—
—
0
0
7
68
1.03
0.08
1.1
1.1
—
—
—
0
0
6
73
0.81
0.08
1.3
1.8
—
—
—
0
0
14
153
0.90
0.08
4.1
1.4
1.79
2.42
g/l
—
9
88
67
657
1.21
0.07
28.7
14.8
66.81
77.38
umol/l
4.37
67
649
27
257
1.08
0.06
2.0
2.0
84.58
97.36
pmol/l
0.76
12
126
29
277
1.08
0.06
5.5
2.9
6.22
6.11
ph
0.22
18
154
21
204
1.04
0.00
2.1
3.2
16.39
38.57
mg/l
1.10
13
137
26
254
1.04
0.00
6.9
3.1
0.00
0.02
estimate
—
9
48
18
182
0.99
0.00
7.9
2.9
0.00
0.00
estimate
—
10
44
16
163
0.98
0.00
4.2
2.8
—
—
—
0
0
20
205
0.97
0.00
2.4
3.8
1.82
5.48
mg/mmol
1.58
13
135
20
196
1.03
0.00
3.0
3.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
67.40
—
0
5
6
69
0.86
-0.00
1.2
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
3.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
270.17
—
0
6
0
5
0.00
-0.00
0.0
1.2
—
204.56
—
0
5
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.2
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: C3_SPINAL_CORD_CRANIAL_AND_OTHER_CNS – Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).